SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078

Oct 25, 2016

SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan

Oct 5, 2016

SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference

Sep 20, 2016

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Aug 31, 2016

SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections

Aug 24, 2016

SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update

Aug 8, 2016

SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference

Aug 4, 2016

SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis

Aug 1, 2016

SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited

Jul 13, 2016

SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Jul 6, 2016